pertuzumabtrastuzumabhyaluronidase sold brand name phesgo fixeddose combination medication treat adults breast cancer spread parts body treatment adults early breast contains pertuzumab trastuzumab injected skin via subcutaneous injection european union phesgo contains active ingredients pertuzumab trastuzumab along enzyme vorhyaluronidase common side effects include alopecia hair loss nausea diarrhea anemia reduced number red blood cells asthenia lack cause worsening chemotherapy induced neutropenia low level white blood may cause harm developing fetus newborn breast cancer makes approximately onefifth breast cancers much protein called human epidermal growth factor receptor promotes growth cancer pertuzumab trastuzumab bind sites disrupt signaling stop cancer cell fixeddose combination indicated treatment early breast cancer ebc treatment metastatic breast cancer mbc fda label includes boxed warning risk potential heart failure fetal harm lung fixeddose combination pertuzumab trastuzumab hyaluronidase approved medical use united states june fdas approval based results noninferiority study participants early breast cancer demonstrated fixeddose combination pertuzumab trastuzumab hyaluronidase comparable efficacy safety iv pertuzumab iv trastuzumab except administrationrelated reactions higher fixeddose combination due subcutaneous route efficacy investigated federica openlabel multicenter randomized trial enrolling participants operable locally advanced breast participants randomized receive neoadjuvant chemotherapy concurrent administration either fixeddose combination pertuzumab trastuzumab hyaluronidase intravenous pertuzumab intravenous trastuzumab neoadjuvant adjuvant primary endpoint federica noninferiority cycle pertuzumab serum trough concentration comparing fixeddose combination pertuzumab trastuzumab hyaluronidase intravenous secondary endpoints included cycle trastuzumab serum trough concentration pathological complete response pcr fixeddose combination showed noninferior pertuzumab trastuzumab serum trough concentrations compared intravenous pertuzumab pcr rate ci pertuzumabtrastuzumabhyaluronidase arm ci intravenous pertuzumab intravenous trastuzumab safety profile fixeddose combination pertuzumab trastuzumab hyaluronidase comparable intravenous pertuzumab trastuzumab except increased administrationrelated fda granted approval phesgo genentech november committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product phesgo intended treatment early metastatic breast applicant medicinal product roche registration phesgo approved medical use european union december httpsenwikipediaorgwikipertuzumabtrastuzumabhyaluronidase